Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : GlaxoSmithKline
Femme et Homme Max 99 ans
GlaxoSmithKline
MAJ Il y a 4 ans
Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroids
To demonstrate a reduction in innate immune response (assessed by priming marker A17 on blood neutrophils) in subjects with asthma treated with the salmeterol/fluticasone propionate combination produc...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
GlaxoSmithKline, S.A
MAJ Il y a 4 ans
Estudio fase IV, multicéntrico, randomizado, doble ciego de 52 semanas de tratamiento, con un periodo de seguimiento abierto de 24 semanas, para evaluar el efecto de Avandia® sobre el tejido óseo de mujeres posmenopáusicas con Diabetes Mellitus tipo 2- A 52 Week Randomized, Double-Blind, Multicenter, Mechanistic Study with a 24 Week Open-Label Follow-Up to Evaluate the Effect of AVANDIA™ on Bone in Postmenopausal Women with Type 2 Diabetes Mellitus
Estimar la diferencia porcentual media en la DMO del cuello femoral, medida por DXA, desde el período basal hasta la semana 52 dentro del grupo tratados con Avandia.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Ofatumumab retreatment and maintenance treatment in patients with CLL
To estimate the proportion of objective responders over 52 weeks to ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL)who progressed following ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
Randomised, double-blind, placebo-controlled study of topical GW842470X formulation in adult patients with moderate atopic dermatitis
To investigate clinical efficacy of 3% GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI)
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A study to test the effectiveness and safety of inhaled GSK2269557 – a potential new medicine for asthma
To investigate the efficacy of inhaled GSK2269557 administered once daily for 28 days in subjects with persistent uncontrolled asthma, compared with placebo.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A randomised, double-blind, placebo-controlled, parallel group study to investigate the anti-inflammatory and metabolic effects of rosiglitazone XR, 8mg once daily, in subjects with rheumatoid arthritis
To assess the anti-inflammatory efficacy of rosiglitazone XR 8 mg administered once daily for a period of 6 months to subjects with rheumatoid arthritis who demonstrate active disease despite disease-...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development
MAJ Il y a 4 ans
A Randomized Double-Blind Placebo-Controlled, Parallel-Group, Multicenter, Study to Evaluate the Efficacy and Safety of GW685698X Inhalation Powder 100mcg, 200mcg, 300mcg and 400mcg Administered Once Daily in the Morning and Fluticasone Propionate 250mcg BID via DISKUS Inhalation Powder Compared with Placebo for 8 Weeks in Adolescent and Adult Subjects (≥12 years old) with Persistent Asthma Symptomatic on Low-Dose ICS Therapy
The objective of this study is to evaluate the dose response, efficacy and safety of four dosage regimens of GW685698X (100mcg, 200mcg, 300mcg and 400mcg) administered once daily in the morning in ado...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Limited
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in Subjects with Stage III and IVA,B Squamous Cell Carcinoma of the Head and Neck (SCCHN)
To evaluate and explore the activity of lapatinib or placebo in the two treatment groups with respect to the complete response rate (per RECIST) at six months (24 weeks) from chemoradiation completion...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research and Development Ltd
MAJ Il y a 4 ans
A double-blind placebo-controlled study of the efficacy and safety of the P38 Map Kinase inhibitor SB681323 in patients with neuropathic pain following nerve trauma
To investigate the effect of SB681323 on the clinical signs of neuropathic pain in patients with nerve trauma and/or compression
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
GlaxoSmithKline Research & Development Ltd
MAJ Il y a 4 ans
A study to compare triple therapy versus dual therapy in patients with asthma
To evaluate the effects of FF/UMEC/VI on lung function compared with FF/VI after 24 weeks of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
6
7
8
9
10
11
12
13
14
15
Suivant